Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features

MLA

Michelle S. Hirsch, et al. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. Nov. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e475dbf338fc3ddf050d82f02f4fa500&authtype=sso&custid=ns315887.

APA

Michelle S. Hirsch, Ziad Bakouny, Abdallah Flaifel, Kerry L. Kilbridge, David A. Braun, Xiao X. Wei, Gordon J. Freeman, Rana R. McKay, David F. McDermott, John A. Steinharter, Lillian Werner, Toni K. Choueiri, Kathryn J. Gray, Ronan Flippot, Sabina Signoretti, Atish D. Choudhury, Eliezer M. Van Allen, Lauren C. Harshman, Bradley Alexander McGregor, & Ulka N. Vaishampayan. (2019). Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.

Chicago

Michelle S. Hirsch, Ziad Bakouny, Abdallah Flaifel, Kerry L. Kilbridge, David A. Braun, Xiao X. Wei, Gordon J. Freeman, et al. 2019. “Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features,” November. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e475dbf338fc3ddf050d82f02f4fa500&authtype=sso&custid=ns315887.